Enzalutamide, an FDA-approved AR inhibitor for prostate cancer, has been shown to reduce cancer stem cell populations and improve survival by 50% in an orthotopic patient-derived xenograft (PDX) model of GBM [81]. The gene discussed is AR; the disease is glioblastoma.